Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5449]

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

A bispecific antibody talquetamab shows promising efficacy in relapsed...

Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands

$A bispecific antibody talquetamab shows promising efficacy in relapsed/refractory multiple myeloma ( Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands )$

Ponatinib and blinatumomab shows complete molecular response for patients with...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

Ponatinib and blinatumomab shows complete molecular response for patients with Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )

Subcutaneous isatuximab administration in combination with pomalidomide...

Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia

Subcutaneous isatuximab administration in combination with pomalidomide-dexamethasone in RRMM can improve convenience and relieve burden for patients ( Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia )

Glofitamab induces durable complete remissions in patients with relapsed large...

Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma ( Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia )

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy...

Prof Barbara Eichhorst - University of Cologne, Cologne, Germany

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia ( Prof Barbara Eichhorst - University of Cologne, Cologne, Germany )

Quizartinib advances overall survival in acute myeloid leukaemia patients

Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA

Quizartinib advances overall survival in acute myeloid leukaemia patients ( Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA )

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy...

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory...

Dr Paul Bröckelmann - University of Cologne, Cologne, Germany

$The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma ( Dr Paul Bröckelmann - University of Cologne, Cologne, Germany )$

Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in...

Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany

Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in frontline CLL ( Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany )

A novel CAR-T cell therapy targeting BCMA is highly effective for patients with...

Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain

$A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain )$

More from ecancer